Charles V Pollack1, Farideh Davoudi2, Deborah B Diercks3, Richard C Becker4, Stefan K James5, Soo Teik Lim6, Phillip J Schulte7, Jindrich Spinar8, Philippe Gabriel Steg9, Robert F Storey10, Anders Himmelmann11, Lars Wallentin5,12, Christopher P Cannon13. 1. Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania. 2. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Department of Emergency Medicine, University of Texas Southwestern, Dallas. 4. Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Ohio. 5. Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Sweden. 6. Department of Cardiology, National Heart Centre, Singapore. 7. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; former employee at Duke Clinical Research Institute, Duke University Medical Center, North Carolina. 8. Department of Internal Medicine/Cardiology, Masaryk University, Brno, Czech Republic. 9. Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Paris, France; Paris Diderot University, Sorbonne Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK; FACT (French Alliance for Cardiovascular Trials), an F-CRIN network, INSERM U1148, Paris, France. 10. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, United Kingdom. 11. AstraZeneca Research and Development, Gothenburg, Sweden. 12. Department of Medical Sciences, Cardiology, Uppsala University, Sweden. 13. Baim Institute for Clinical Research, and Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Guidelines suggest that "upstream" P2Y12 receptor antagonists should be considered in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). HYPOTHESIS: Early use of ticagrelor in patients managed with an invasive strategy would be more effective than clopidogrel because of its more rapid onset of action and greater potency. METHODS: In the PLATO trial, 6792 NSTE-ACS patients were randomized to ticagrelor or clopidogrel (started prior to angiography) and underwent angiography within 72 hours of randomization. We compared efficacy and safety outcomes of ticagrelor vs clopidogrel as a function of "early" (<3h) vs "late" (≥3h) time to angiography. Adjusted Cox proportional hazards models evaluated interaction between randomized treatment and time from randomization to angiography on subsequent outcomes. RESULTS: Overall, a benefit of ticagrelor vs clopidogrel for cardiovascular death/myocardial infarction/stroke was seen at day 7 (hazard ratio [HR]: 0.67, P = 0.002), day 30 (HR: 0.81, P = 0.042), and 1 year (HR: 0.80, P = 0.0045). There were no significant interactions in the <3h vs ≥3h groups at any timepoint. For major bleeding, overall there was no significant increase (HR: 1.04, 95% confidence interval: 0.85-1.27); but there was a significant interaction with no difference between ticagrelor and clopidogrel in the early group (HR: 0.79), but higher bleeding risk with ticagrelor in the late angiography group, at 7 days (HR: 1.51, Pint = 0.002). Patterns were similar at 30 days and 1 year. CONCLUSIONS: The benefit of ticagrelor over clopidogrel was consistent in those undergoing early and late angiography, supporting upstream use of ticagrelor.
RCT Entities:
BACKGROUND: Guidelines suggest that "upstream" P2Y12 receptor antagonists should be considered in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). HYPOTHESIS: Early use of ticagrelor in patients managed with an invasive strategy would be more effective than clopidogrel because of its more rapid onset of action and greater potency. METHODS: In the PLATO trial, 6792 NSTE-ACSpatients were randomized to ticagrelor or clopidogrel (started prior to angiography) and underwent angiography within 72 hours of randomization. We compared efficacy and safety outcomes of ticagrelor vs clopidogrel as a function of "early" (<3h) vs "late" (≥3h) time to angiography. Adjusted Cox proportional hazards models evaluated interaction between randomized treatment and time from randomization to angiography on subsequent outcomes. RESULTS: Overall, a benefit of ticagrelor vs clopidogrel for cardiovascular death/myocardial infarction/stroke was seen at day 7 (hazard ratio [HR]: 0.67, P = 0.002), day 30 (HR: 0.81, P = 0.042), and 1 year (HR: 0.80, P = 0.0045). There were no significant interactions in the <3h vs ≥3h groups at any timepoint. For major bleeding, overall there was no significant increase (HR: 1.04, 95% confidence interval: 0.85-1.27); but there was a significant interaction with no difference between ticagrelor and clopidogrel in the early group (HR: 0.79), but higher bleeding risk with ticagrelor in the late angiography group, at 7 days (HR: 1.51, Pint = 0.002). Patterns were similar at 30 days and 1 year. CONCLUSIONS: The benefit of ticagrelor over clopidogrel was consistent in those undergoing early and late angiography, supporting upstream use of ticagrelor.
Authors: Christian W Hamm; Jean-Pierre Bassand; Stefan Agewall; Jeroen Bax; Eric Boersma; Hector Bueno; Pio Caso; Dariusz Dudek; Stephan Gielen; Kurt Huber; Magnus Ohman; Mark C Petrie; Frank Sonntag; Miguel Sousa Uva; Robert F Storey; William Wijns; Doron Zahger Journal: Eur Heart J Date: 2011-08-26 Impact factor: 29.983
Authors: Hani Jneid; Jeffrey L Anderson; R Scott Wright; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson Journal: Circulation Date: 2012-07-16 Impact factor: 29.690
Authors: Philippe Gabriel Steg; Stefan James; Robert A Harrington; Diego Ardissino; Richard C Becker; Christopher P Cannon; Håkan Emanuelsson; Ariel Finkelstein; Steen Husted; Hugo Katus; Jan Kilhamn; Sylvia Olofsson; Robert F Storey; W Douglas Weaver; Lars Wallentin Journal: Circulation Date: 2010-11-08 Impact factor: 29.690
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Deborah B Diercks; Michael C Kontos; Judd E Hollander; Bryn E Mumma; DaJuanicia N Holmes; Stephen Wiviott; Jorge F Saucedo; James A de Lemos Journal: Am J Emerg Med Date: 2013-05-20 Impact factor: 2.469
Authors: Paul A Gurbel; Kevin P Bliden; Kathleen Butler; Udaya S Tantry; Tania Gesheff; Cheryl Wei; Renli Teng; Mark J Antonino; Shankar B Patil; Arun Karunakaran; Dean J Kereiakes; Cordel Parris; Drew Purdy; Vance Wilson; Gary S Ledley; Robert F Storey Journal: Circulation Date: 2009-11-18 Impact factor: 29.690
Authors: Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-02-28
Authors: Charles V Pollack; W Frank Peacock; Durgesh D Bhandary; Steven H Silber; Narinder Bhalla; Sunil V Rao; Deborah B Diercks; Alex Frost; Sripal Bangalore; John F Heitner; Charles Johnson; Renato DeRita; Naeem D Khan Journal: Crit Pathw Cardiol Date: 2020-12